BioNet at MSS2026 BioNet is pleased to participate in MSS2026, the next-gen bioManufacturing & delivery Science Symposium, taking place from 14-16 September 2026 in Bled, Slovenia. The symposium brings together scientists, researchers, and industry leaders to discuss the latest advances in…
An Expert Perspective on a New Recombinant Pertussis-Only Vaccine and Its Potential Clinical and Programmatic Advantages in Australia, New Zealand, and Beyond
An Expert Perspective on a New Recombinant Pertussis-Only Vaccine and Its Potential Clinical and Programmatic Advantages in Australia, New Zealand, and Beyond The publication highlights expert perspectives on the latest developments in pertussis prevention and the potential advantages of a new…
Two Presentations on BioNet’s Recombinant Pertussis Vaccines Received Awards at ACPID 2026
Two presentations highlighting BioNet’s recombinant pertussis vaccine research received awards at the Asian Congress of Pediatric Infectious Diseases (ACPID) 2026, held from 14–16 August in Indonesia. Dr. Kulkanya Chokephaibulkit received the 1st Winner award for Oral Presentation for “Thailand’s Experience with Recombinant…
Safety and immunogenicity of a genetically inactivated stand-alone acellular pertussis vaccine as a booster to Australian adults: a randomized, controlled, non-inferiority trial
A Step Forward for Pertussis Prevention: BioNet’s “Safety and immunogenicity of a genetically inactivated stand-alone acellular pertussis vaccine as a booster to Australian adults: a randomized, controlled, non-inferiority trial” Published in Vaccine. Key Highlights 🎯 A total of 102 healthy Australian…
European Immunization Week 2026: For every generation, vaccines work
European Immunization Week 2026: For every generation, vaccines work This week, Europe celebrates the immunization week focusing on the vaccination of people of all ages. Infectious diseases can affect you during your entire lifetime. Vaccines have proven their effectiveness to protect…
EU Centralised Authorisation of BioNet’s Pertussis‑Only Vaccine
EU Centralised Authorisation of BioNet’s Pertussis‑Only Vaccine Medicines intended for use across the European Union may be assessed through the centralised authorisation procedure coordinated by the European Medicines Agency. BioNet pertussis-only vaccine was evaluated under this framework to ensure a harmonised…
Role of Pertussis Booster Vaccination in EU Immunisation Strategies
Role of Pertussis Booster Vaccination in EU Immunisation Strategies Booster vaccination plays a central role in pertussis prevention across the European Union. While primary vaccination provides early protection, immunity wanes over time, underscoring the importance of booster doses for adolescents, adults,…
An Alternative to Pertussis Combination Vaccines for Booster Use
An Alternative to Pertussis Combination Vaccines for Booster Use Combination vaccines containing pertussis, tetanus, and diphtheria antigens have played a central role in pertussis prevention for many years. However, not all individuals requiring pertussis booster vaccination need repeated immunisation against tetanus…
Maternal Immunisation and Passive Protection of Newborns
Maternal Immunisation and Passive Protection of Newborns Maternal vaccination is a proven way to protect young babies from pertussis (whooping cough) during their first months of life, before they finish their primary vaccination series. BioNet’s pertussis‑only vaccine is approved for use…
A Focused Strategy Against Pertussis Toxin
A Focused Strategy Against Pertussis Toxin Pertussis toxin is a central virulence factor of Bordetella pertussis and is closely associated with the severe clinical manifestations of whooping cough. The scientific rationale for BioNet’s pertussis-only vaccine is based on inducing immune responses…